1
Gary G Liversidge, Elaine Liversidge, Pramod P Sarpotdar: Surface modified anticancer nanoparticles. Eastman Kodak Company, Arthur H Rosenstein, March 21, 1995: US05399363 (279 worldwide citation)

Dispersible particles consisting essentially of a crystalline anticancer agent having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 1000 nm. Anticancer compositions comprising the particles exhibit reduced ...


2
Gary G Liversidge, Elaine Liversidge, Pramod P Sarpotdar: Surface modified anticancer nanoparticles. Eastman Kodak Company, Arthur H Rosenstein, February 27, 1996: US05494683 (105 worldwide citation)

Dispersible particles consisting essentially of a crystalline anticancer agent having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 1000 nm. Anticancer compositions comprising the particles exhibit reduced ...


3
Elaine Liversidge, Greta A Gottardy, Linden Wei: Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions. Klan Pharma International, Foley & Lardner, July 31, 2001: US06267989 (105 worldwide citation)

The present invention is directed to methods for preventing crystal growth and particle aggregation in nanoparticulate compositions. The methods comprise reducing a nanoparticulate composition to an optimal effective average particle size. The resultant nanoparticulate compositions exhibit prolonged ...


4
Elaine Liversidge, Greta A Gottardy: Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions. Elan Pharma International, Foley & Lardner, August 7, 2001: US06270806 (86 worldwide citation)

Nanoparticulate compositions comprising an insoluble organic drug and at least one polyethylene glycol-derivatized lipid adsorbed on the surface of the drug are described. The polyethylene glycol-derivatized lipid can be a PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, ...


5
Kenneth E Kellar, Piotr H Karpinski, Elaine Liversidge, Wolfgang H H Gunther, Gregory L McIntire, Barbara Van Orman: Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents. Sterling Winthrop, William J Davis, March 28, 1995: US05401492 (45 worldwide citation)

This invention is directed to a magnetic resonance imaging composition for imaging of an organ rich in mitochondria comprising particles of a substantially insoluble manganese compound. In a preferred embodiment, the organ rich in mitochondria is the liver. In a further preferred embodiment, the par ...


6
H William Bosch, Elaine Liversidge, Suhas D Shelukar, Karen C Thompson: Pharmaceutical composition of a tachykinin receptor antagonist. Merck Sharp & Dohme, Yong Zhao, David A Muthard, Nicole M Beeler, September 4, 2012: US08258132

The present invention is directed to novel pharmaceutical compositions of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine. The pharmaceutical compositions of this invention useful in the treatment or preventio ...


7
Lawrence de Garavilla, Elaine Liversidge, Gary G Liversidge: Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions. Elan Pharma International, Wenderoth Lind & Ponack L, October 26, 2010: USRE041884

Disclosed are methods of intravenous administration of nanoparticulate drug formulations to a mammal to avoid adverse hemodynamic effects: by reducing the rate and concentration of the nanoparticles in the formulations; or by pre-treating the subject with histamine; or by pretreating the subject wit ...


8
Kenneth E Kellar, Piotr H Karpinski, Elaine Liversidge: Water insoluble manganese particles as magnetic resonance contrast enhancement agents. Sterling Winthrop, TIAN MINGSHENG LUO CAIXI, May 10, 1995: CN93119681

This invention is directed to a magnetic resonance imaging composition for imaging of an organ rich in mitochondria comprising particles of a substantially insoluble manganese compound. In a preferred embodiment, the organ rich in mitochondria is the liver. In a further preferred embodiment, the par ...


9
James Cunningham, Elaine Liversidge, Eugene R Cooper, Gary G Liversidge: Milling microgram quantities of nanoparticulate candidate compounds. Elan Pharma International, Foley And Lardner, September 9, 2004: US20040173696-A1

The present invention is directed to a method of milling small quantities of one or more candidate compounds to reduce the particle size of at least one candidate compound to about 2 microns or less. The apparatus used for the milling process can be one or more multi-well plates, or any other suitab ...


10
H William Bosch, Elaine Liversidge, Suhas D Shelukar, Karen C Thompson: Pharmaceutical composition of a tachykinin receptor antagonist. Merck And Co, October 28, 2004: US20040214746-A1

The present invention is directed to novel pharmaceutical compositions of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine. The pharmaceutical compositions of this invention useful in the treatment or preventio ...